• Curvebeam AI is commercialising a new medical device, the HiRise™, a cone beam CT scanner that scans a patient's lower extremity under their own body weight
• HiRise™ is FDA cleared, TGA listed, and CE marked, and has been clinically validated and adopted by leading medical institutions
• Curvebeam AI has a partnership with Stryker Corporation's Foot & Ankle division to sell the HiRise™

Curvebeam AI Ltd (ASX: CVB) has released an investor deck providing an overview of the company and its new medical device, the HiRise™. The HiRise™ is a cone beam CT scanner that can scan a patient's lower extremity (i.e. hip, knee, ankle, foot) while the patient is under their own body weight. This allows for superior diagnostic imaging that can better evaluate how joints and bones behave under load, providing a more realistic and detailed view of the skeleton for surgical planning. The HiRise™ is FDA cleared, TGA listed, and CE marked, and has been clinically validated with dozens of published studies. It has been adopted by leading medical institutions and recognised clinical thought leaders. Curvebeam AI has also partnered with Stryker Corporation's Foot & Ankle division, a Nasdaq-listed company and one of the largest orthopaedic companies, to sell the HiRise™. The investor deck outlines the market opportunity, particularly targeting surgeon practices, as the HiRise™ provides an easy-to-use point-of-care solution that saves time, provides an additional profit centre for surgeons, and improves workflow by allowing patients to undergo CT and bone mineral density scans in a single visit. The deck also discusses Curvebeam AI's growth strategy, including its global partner and distribution network, as well as its plans to validate the enhanced HiRise™ for use with leading robotic surgery devices for knee and hip procedures. Additionally, Curvebeam AI has entered into a non-binding term sheet with a Chinese medical device distributor/manufacturer for the potential exclusive distribution of its products in China, Hong Kong, Macau, and Taiwan, as well as a manufacturing and equity investment agreement.

Curvebeam AI is continuing to roll out the HiRise™ device and has several key potential growth drivers, including the vendor financing option, the enhanced HiRise™ robotic device validation, and the recently announced potential partnership and manufacturing agreement in China.